Advaxis' Cervical Cancer Vaccine Approved for Human Testing
Posted on: Thursday, 23 February 2006, 12:00 CST
The FDA has given its go-ahead for Advaxis to begin testing its listeria based cervical cancer vaccine, Lovaxin C, in humans. The company now expects to begin phase I/II trials of the compound by the end of February.
Pre-clinical data for Lovaxin C demonstrates an extremely robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the animals tested.
Unlike other products in late clinical trials, which are preventative vaccines against the HPV virus (the virus which causes cervical cancer), but cannot benefit woman already infected with the virus. The Advaxis vaccine, Lovaxin C is a therapeutic designed to treat women who have developed cervical cancer as a result of an HPV infection. Advaxis says that it is targeting this significant unmet medical need with the Lovaxin C vaccine.
"This Phase I/II trial is the first step in a comprehensive plan that will build on the strong pre-clinical results we have seen in more than a decade of development work," said Roni Appel, president and CEO of Advaxis.
Source: Datamonitor
Related Articles
- Cancer Vaccines Are the Newest Weapon in the Battle Against Cancer
- Advaxis Begins Patient Education Initiative to Promote Better Understanding of Cervical Cancer Vaccines; Vice President of Clinical Development Interviewed By Television Stations Nationwide
- Cervical Cancer Vaccine Up for FDA Review
- Advaxis Advances Therapeutic Cervical Cancer Vaccine in Effort to Save Lives Early
- Advaxis Enrolls Patients to Cervical Cancer Vaccine Trial
- Advaxis' Listeria Cancer Vaccine Receives Regulatory Approval for Phase I/II Testing in Cervical Cancer
- Advaxis' Listeria Cancer Vaccine Results in Complete Regression of Rapidly Growing Breast Tumors
- Advaxis' Listeria Cancer Vaccine Shows Strong Safety Profile In Toxicology Studies
- Cervical Cancer Vaccine Shows Promise
 |
 |
User Comments (0)
RSS Feeds